Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, has announced the pricing of its concurrent public offerings of 7,857,143 shares of common stock, at a public offering price of US$35 per share, and US$225 million aggregate principal amount of 2.00% convertible senior notes due 2032. The issuance and sale of the common stock and the notes are scheduled to settle on September 25, 2026, subject to customary closing conditions. Viking also granted the underwriters of the common stock offering a 30-day option to purchase up to an additional 1,178,571 shares of common stock and granted the underwriters of the notes offering a 30-day option to purchase up to an additional US$33.75 million aggregate principal amount of notes.
Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by Orange County partners Ross McAloon and Shayne Kennedy, San Diego partner Matt Bush, and New York/Los Angeles partner Greg Rodgers.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
